MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/09612033261449985

Медицинская библиотека · Lupus · 2026

Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis.

Abe Yoshiyuki, Makiyama Ayako, Minowa Kentaro, Uchiyama Saki, Kogami Masahiro, Takeuchi Motoki, Tanaka Yoshiya, Hiromura Keiju, Hayashi Hiroki, Kamada Kazuro, Kawahito Yutaka, Iwashita Akiho, Kaname Shinya, Shimizu Hayato, Yasuda Shinsuke, Hiramoto Kazuoto, Maruyama Shoichi, Yajima Nobuyuki, Iwata Yasunori, Matsumoto Isao, Gono Takahisa, Sato Hiroko, Kubo Satoshi, Ikeuchi Hidekazu, Yuzawa Yukio, Kono Michihito, Seno Takahiro, Onishi Akira, Kawakami Takahisa, Hosoya Tadashi, Kaneko Yuko, Kato Sawako, Nakagawa Shiori, Kondo Yuya, Kuwana Masataka, Ishii Tomonori, Atsumi Tatsuya, Ohmura Koichiro, Tamura Naoto

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

ObjectiveTo evaluate the effectiveness of a lower initial glucocorticoid (GC) dose (0.4-0.6 mg/kg/day) compared to the conventional dose (0.8-1.2 mg/kg/day) in achieving complete renal response (CRR) at 12 months in Japanese patients with proliferative lupus nephritis (LN).MethodsThis multicentre, retrospective observational study analyzed data from 344 Japanese patients diagnosed with LN (class III or IV ± V) via renal biopsy. Patients were divided into two groups based on their initial dose of GC. 1:1 propensity score matching (PSM) based on key baseline variables, 23 patients were included in each group. The primary endpoint was CRR at 12 months, defined according to the BLISS-LN trial criteria. A non-inferiority margin of -10% was prespecified.ResultsAfter PSM, the CRR rate at 12 months was 87.0% in the low-dose group and 73.9% in the conventional-dose group (risk difference: 13.1%; 95% confidence interval [CI]: -9.4% to 35.6%), confirming statistical non-inferiority. While GC doses differed significantly during the initial 3 months, they became comparable between the groups after 6 months.ConclusionA reduced initial GC dose of 0.4-0.6 mg/kg/day achieved renal outcomes comparable to conventional dosing in Japanese patients with LN. Given the risks of GC toxicity, these findings may support the potential for lower-dose GC strategies in LN treatment.

Для цитирования: Abe Yoshiyuki, Makiyama Ayako, Minowa Kentaro, Uchiyama Saki, Kogami Masahiro, Takeuchi Motoki, Tanaka Yoshiya, Hiromura Keiju, Hayashi Hiroki, Kamada Kazuro, Kawahito Yutaka, Iwashita Akiho, Kaname Shinya, Shimizu Hayato, Yasuda Shinsuke, Hiramoto Kazuoto, Maruyama Shoichi, Yajima Nobuyuki, Iwata Yasunori, Matsumoto Isao, Gono Takahisa, Sato Hiroko, Kubo Satoshi, Ikeuchi Hidekazu, Yuzawa Yukio, Kono Michihito, Seno Takahiro, Onishi Akira, Kawakami Takahisa, Hosoya Tadashi, Kaneko Yuko, Kato Sawako, Nakagawa Shiori, Kondo Yuya, Kuwana Masataka, Ishii Tomonori, Atsumi Tatsuya, Ohmura Koichiro, Tamura Naoto. Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis.. Lupus. 2026. DOI: 10.1177/09612033261449985.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.